Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 3/20 | 0.46 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.45 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10874696 | 0.84 | GSK3B (0.51) | GSK3BCES2CES1DAOGAA | |
| SCHEMBL28407046 | 0.81 | PLOD2 (0.47) | GSK3BCES1DAOPLOD2PLOD3 | |
| SCHEMBL10876692 | 0.81 | GSK3B (0.59) | GSK3BDAOGAAKDM4EPLOD2 | |
| SCHEMBL5551328 | 0.79 | DAO (0.48) | DAOPLOD2PLOD3PLOD1KMT2A | |
| SCHEMBL28409166 | 0.79 | PLOD2 (0.46) | GSK3BCES1DAOPLOD2PLOD3 | |
| SCHEMBL14624168 | 0.77 | GSK3B (0.63) | GSK3BCES2CES1DAOGAA | |
| SCHEMBL8981404 | 0.76 | GSK3B (0.58) | GSK3BCES2CES1DAOGAA | |
| SCHEMBL2227006 | 0.76 | CES2 (0.59) | GSK3BCES2CES1DAOGAA | |
| SCHEMBL3472612 | 0.76 | GSK3B (0.68) | GSK3BCES2CES1DAOGAA | |
| SCHEMBL3461763 | 0.76 | PLOD2 (0.42) | GSK3BCES1DAONPSR1PLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986888-A1 | THIENYLHYDROXYISOXAZOLINES AND DERIVATIVES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2820013-B9 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS INC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180370959-A1 | Liver X. Receptor (LXR) Modulators for the Treatment of Dermal Diseases, Disorders and Conditions | ALEXAR THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-2820013-B1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007055767-A1 | MOLECULARLY IMPRINTED POLYMER ION EXCHANGE RESINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-7067702-B2 | Process for preparing vinyl substituted beta-diketones | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060069288-A1 | Process for preparing vinyl substituted beta-diketones | THE JOHNS HOPKINS UNIVERSITY | 2006-03-30 | — | — | US | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | GSK3B 2926/4885CES2 1523/4885CES1 193/4885 |
| US-20180370959-A1 | Liver X. Receptor (LXR) Modulators for the Treatment of Dermal Diseases, Disorders and Conditions | NR1H2, NR1H3, RXRA | GSK3B 442/4885CES2 468/4885CES1 75/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | GSK3B 451/4885CES2 454/4885CES1 74/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | GSK3B 512/4885CES2 514/4885CES1 73/4885 |
| US-20060069288-A1 | Process for preparing vinyl substituted beta-diketones | VRK1, VRK2, DEK | GSK3B 528/4885CES2 2479/4885CES1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.